<?xml version="1.0" encoding="UTF-8"?><feed xmlns="http://www.w3.org/2005/Atom">
  <title>医药笔记 | wechat-feeds</title>
  <id>https://github.com/hellodword/wechat-feeds</id>
  <updated>2021-01-22T20:50:11+08:00</updated>
  <link href="https://github.com/hellodword/wechat-feeds"></link>
  <author>
    <name>hellodword</name>
  </author>
  <entry>
    <title>石药集团抗体药全梳理</title>
    <updated>2021-01-22T19:52:58+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-22:/s/esNDXS9v0I2i_caW-8D0AQ</id>
    <link href="https://mp.weixin.qq.com/s/esNDXS9v0I2i_caW-8D0AQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>Incyte向FDA递交PD-1抗体上市申请，再鼎医药拥有中国权益</title>
    <updated>2021-01-22T19:52:58+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-22:/s/kD7szZ36wREGtU8BY4DEew</id>
    <link href="https://mp.weixin.qq.com/s/kD7szZ36wREGtU8BY4DEew" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>默克PD-L1/TGFβ双抗临床失败，国内多家药企在研</title>
    <updated>2021-01-20T23:34:27+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-20:/s/defcN2cQrJteNlk8M9U06Q</id>
    <link href="https://mp.weixin.qq.com/s/defcN2cQrJteNlk8M9U06Q" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>Merus与礼来达成16.8亿美元合作，贝达药业、先声药业均引进其双抗</title>
    <updated>2021-01-20T06:50:01+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-20:/s/ktxMT2516mHJasdLdsIbkQ</id>
    <link href="https://mp.weixin.qq.com/s/ktxMT2516mHJasdLdsIbkQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>CD47-SIRPα轴肿瘤免疫疗法：靶向SIRPα</title>
    <updated>2021-01-20T06:50:01+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-20:/s/aPa4bguxBDETWRbtFmMAaQ</id>
    <link href="https://mp.weixin.qq.com/s/aPa4bguxBDETWRbtFmMAaQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>国内首家：东阳光申报GLP-1/FGF21双功能分子</title>
    <updated>2021-01-20T06:50:01+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-20:/s/lH7r0aY4Iy91olis96_WVw</id>
    <link href="https://mp.weixin.qq.com/s/lH7r0aY4Iy91olis96_WVw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>东阳光申报德谷胰岛素：国内第6家</title>
    <updated>2021-01-20T06:50:01+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-20:/s/UaOa_1bS6G1Ju901eU8ZoA</id>
    <link href="https://mp.weixin.qq.com/s/UaOa_1bS6G1Ju901eU8ZoA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>2020年国内大分子新药研发格局</title>
    <updated>2021-01-19T08:58:29+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-19:/s/mPJzGHhGLoplDLRF5NI48g</id>
    <link href="https://mp.weixin.qq.com/s/mPJzGHhGLoplDLRF5NI48g" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>纽福斯申报眼病基因疗法NR082</title>
    <updated>2021-01-19T08:58:29+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-19:/s/eapIVVhHVH6skpRdehOIPw</id>
    <link href="https://mp.weixin.qq.com/s/eapIVVhHVH6skpRdehOIPw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>北京科兴新冠疫苗获巴西批准</title>
    <updated>2021-01-18T11:21:48+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-18:/s/B4vegY1Bn8F3TOTDRa1CaQ</id>
    <link href="https://mp.weixin.qq.com/s/B4vegY1Bn8F3TOTDRa1CaQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>Blood：默沙东ROR1 ADC药物治疗里氏转化淋巴瘤</title>
    <updated>2021-01-17T20:42:08+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-17:/s/aUhuGeiUKtdRvl6WwwbjRg</id>
    <link href="https://mp.weixin.qq.com/s/aUhuGeiUKtdRvl6WwwbjRg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>ABL Bio：B7-H3/4-1BB双抗</title>
    <updated>2021-01-17T20:42:08+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-17:/s/ZnEF98O2B03m2R8b34Nrpg</id>
    <link href="https://mp.weixin.qq.com/s/ZnEF98O2B03m2R8b34Nrpg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>DS-8201获FDA批准治疗胃癌</title>
    <updated>2021-01-16T09:13:10+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-16:/s/xlXlyRivd5jMt3ZgT3IHVA</id>
    <link href="https://mp.weixin.qq.com/s/xlXlyRivd5jMt3ZgT3IHVA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>CD38抗体Darzalex获批第二个适应症：轻链淀粉样变性</title>
    <updated>2021-01-16T09:13:10+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-16:/s/UKjPs1XNQdaLuq1do4ZG4w</id>
    <link href="https://mp.weixin.qq.com/s/UKjPs1XNQdaLuq1do4ZG4w" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>友芝友新型双抗平台：四价对称</title>
    <updated>2021-01-15T07:29:11+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-15:/s/v8FumQ9XiweEEY1pgmmh8w</id>
    <link href="https://mp.weixin.qq.com/s/v8FumQ9XiweEEY1pgmmh8w" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>细胞因子新疗法：BioNtech启动IL-2+IL-7临床试验</title>
    <updated>2021-01-15T07:29:11+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-15:/s/mzX383uxcWGsEEegNizzwQ</id>
    <link href="https://mp.weixin.qq.com/s/mzX383uxcWGsEEegNizzwQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>金斯瑞研发PD-1/CD47双抗</title>
    <updated>2021-01-15T07:29:11+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-15:/s/Cb0J2391WKo1lSIzzJIT-A</id>
    <link href="https://mp.weixin.qq.com/s/Cb0J2391WKo1lSIzzJIT-A" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>复宏汉霖1.1亿美元引进Trop2抗体</title>
    <updated>2021-01-15T07:29:11+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-15:/s/dLgkKAtZn2cm7cWkiQCvdw</id>
    <link href="https://mp.weixin.qq.com/s/dLgkKAtZn2cm7cWkiQCvdw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>NEJM：不同种族、癌种KRAS G12C突变分布</title>
    <updated>2021-01-14T12:10:42+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-14:/s/c7i2bjgUUX466GZtLlKSWg</id>
    <link href="https://mp.weixin.qq.com/s/c7i2bjgUUX466GZtLlKSWg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>补体新秀：科越医药JPM会议首度亮相</title>
    <updated>2021-01-14T12:10:42+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-14:/s/Hn1cg5pYaV8agPp2NYDusA</id>
    <link href="https://mp.weixin.qq.com/s/Hn1cg5pYaV8agPp2NYDusA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
</feed>